All News

Software agents could change the way that computing works. You just leave them to get on with the work.

Every business has to issue a press release one day. When they do so, they should remember that jargon does not help get the message across.

Universities in Ireland can now bid for funds to beef up their knowledge transfer activities.

In an earlier blog, I deplored the lack of data about the European IP market and in particular about the academic licensing business. I am delighted to report that my “bottle in the ocean” approach has produced results.

Active Solar Buildings – entirely heated and cooled by solar thermal energy – should become the standard by 2030 if the vision of the EU’s latest Technology Platform is realised.

A group of researchers, led by Mark Pepys, at University College London has designed and chemically synthesised a new drug, which they have shown to reduce heart tissue damage following a heart attack.

An unusual programme by the software giant to spin out its technology has netted nine sales to small companies - with more on the way.

Drug companies finally have an incentive to carry out safety testing in children following new EU legislation approved last week.

A laser physicist in Saudi Arabia has devised a workable optical diagnostic tool to detect early cancer - and is now looking for partners to commercialise the technology.

The first protein drug extracted from the milk of a genetically modified animal has finally received European approval.

Scientists from the University of Birmingham, UK, have powered a fuel cell from confectionary waste. They now want to form a consortium with investors and SMEs to apply for an EU Framework grant.

The Open Source software movement has broken the stranglehold of expensive, proprietary products. Could the same thing happen in biotechnology?

The Finnish developers of a new and tiny silicon-based timer circuit are looking for partners with application-specific engineering and marketing expertise to take the product further.

Advances in neuroscience are opening up the treatment options for central nervous system diseases - at the same time as the ageing population is increasing the market for these products.

The TeGenero drug trial is complete, and an ongoing study is examing whether trial requirements should be changed. But, asks Nuala Moran, should the trial ever have been approved?